Breakthrough Therapy | Savara's Molbreevi, a potential first-in-class treatment for aPAP, completes BLA submission with promising Phase 3 data and Breakthrough Therapy designation |
Market Opportunity | Explore the expanded addressable market for aPAP treatment, with over 7,000 potential patients in the U.S. and projected peak sales exceeding $1 billion |
Financial Outlook | Delve into Savara's financial strategy, including $173M cash reserves and a $200M debt agreement, supporting operations through potential 2026 product launch |
Analyst Projections | Analyst price targets range from $2 to $16 per share, with Wells Fargo and JMP Securities maintaining bullish outlooks of $7 and $9, respectively |
Metrics to compare | SVRA | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipSVRAPeersSector | |
|---|---|---|---|---|
P/E Ratio | −10.0x | −2.7x | −0.3x | |
PEG Ratio | 0.77 | −0.03 | 0.00 | |
Price/Book | 9.7x | 2.2x | 2.6x | |
Price / LTM Sales | - | 12.7x | 3.1x | |
Upside (Analyst Target) | 90.9% | 112.4% | 50.4% | |
Fair Value Upside | Unlock | −1.8% | 6.4% | Unlock |
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases in the United States. The company’s lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. was founded in 2007 and is headquartered in Yardley, Pennsylvania.